Droia Ventures

Matthias Van Woensel, Partner at Droia Ventures, and Mathias De Decker are gearing up for BIO-Europe 2024 in Stockholm from November 4th to 6th! With a strong focus on advancing innovative biotech solutions and connecting with like-minded professionals, they are eager to discuss partnerships. BIO-Europe is the perfect stage for valuable exchanges, networking, and fostering collaborations. Are you attending? Don’t hesitate to reach out—they’d love to connect and discuss how we can shape the future of biotech together. #BIOEurope2024 #biotech #healthcareinnovation #DroiaVentures #Stockholm

📢 NEWS: The FDA has cleared our Investigational New Drug (IND) application for ATX-559, our first-in-class oral DHX9 inhibitor, paving the way for a Phase 1/2 trial focused on patients with BRCA1/2-deficient breast cancer and solid tumors with microsatellite instability and/or deficient mismatch repair (NCT06625515). Learn more: https://bit.ly/40bAbmq #cancerresearch #drugdevelopment #DHX9 #clinicaltrial #breastcancer #colorectalcancer

Our colleague, Rindert Missiaen is very much looking forward to attend the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics.  The symposium, also known as the “triple meeting 2024”, will take place October 23-25, 2024 in Barcelona, Spain.  Rindert is eager to meet and network with clinical researchers and scientists as well as fellow industry delegates in the field of drug discovery and targets in cancer, ensuring in-depth scientific discussion on the latest developments.  #Symposium #moleculartargets #cancertherapeutics #ENA2024 #CCIB

Dieter Petit, PhD Associate Droia Ventures, will be attending the prestigious ESGCT Congress (European Society of Gene and Cell Therapy) in Rome from October 22 to 25, 2024. The #ESGCT2024 Congress is a leading event in the field, where experts and pioneers in gene and cell therapy gather to discuss the latest innovations and advancements. Dieter is looking forward to engaging with fellow professionals and contributing to the insightful discussions. Will you be joining him? #ESGCT2024 #CellTherapy #Genetherapy

Great opportunities ahead as Lawrence Van Helleputte, Associate, and Mathias De Decker, Senior Analyst, head to Munich for AbbVie Partnering Day! It's a fantastic opportunity to connect, learn and meet with AbbVie's research and partnership leadership teams. Wishing them both a productive and inspiring trip! #PartneringDay #Innovation #Oncology #Immunology

We are pleased to announce that two of our colleagues are taking the next step in their careers. Mathias Declercq, who has been with us since December 2021, has been promoted to Senior Associate. Mathias De Decker, who joined the team in November 2023, has advanced to the role of Senior Analyst. Congratulations to both on their well-deserved achievements. #OneTeamOneGoal

Judo Bio launches with $100 million in combined seed and Series A financing from leading investors to advance an initial pipeline designed to silence mRNA in the proximal tubule epithelial cells of the kidney. #siRNAtotheKidney https://lnkd.in/giEF8tnM

🌟 Exciting News! 🌟 We're thrilled to announce that Dieter Petit, PhD and Mathias Declercq will be attending ASGCT in Baltimore next week! Looking forward to connecting with fellow innovators and experts in the field. If you're attending as well, they’d love to meet up and discuss innovative research and upcoming therapies. Feel free to reach out to them or connect at the conference. See you there! #ASGCT #GeneTherapy #NetworkingOpportunity

🎉 I’m thrilled to announce that Hendrik De Smedt joined Droia Ventures as our new Director of Finance! Hendrik brings a wealth of experience in finance, having worked in audit and financial controlling roles. Let’s send our best wishes to Hendrik as he embarks on this exciting journey with Droia Ventures! 🚀

Proud to continue supporting Frontier Medicines! Congratulations to the team!